Homepage
Author:
Cocrystal Pharma, Inc.
Posted Date:
June 3, 2026
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
Cocrystal Pharma, Inc.
June 3, 2026
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza
Cocrystal Pharma, Inc.
May 26, 2026
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
Cocrystal Pharma, Inc.
May 21, 2026
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
Cocrystal Pharma, Inc.
April 2, 2026
Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma, Inc.
March 31, 2026
First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
Cocrystal Pharma, Inc.
March 9, 2026
Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
Cocrystal Pharma, Inc.
February 19, 2026
